Pelkonen O
Department of Pharmacology and Toxicology, University of Oulu, Finland.
Scand J Work Environ Health. 1992;18 Suppl 1:17-21.
Many chemical carcinogens need activation by drug metabolizing enzymes, principally cytochrome P450 enzymes, to become capable of binding to deoxyribonucleic acid and initiating the carcinogenic process. The activity and inducibility of drug metabolizing enzymes are regulated by interplay between genetic, host, and environmental factors. Consequently, individual differences in cancer susceptibility might be explained somewhat by genetic differences in metabolic activation. Three examples, the induction of aryl hydrocarbon (benzo[a]pyrene) hydroxylase by polycyclic aromatic hydrocarbons, polymorphic debrisoquine/sparteine oxidation, and polymorphic acetylation, are briefly reviewed. Despite useful animal models and promising early human findings, no consensus has been reached about the significance of genetically based differences in drug metabolism in cancer etiology. It is expected that, with the use of molecular biological methods, the genetic background of study subjects can be investigated without bias caused by the disease, age, treatment, or other factors which have plagued investigations thus far.
许多化学致癌物需要通过药物代谢酶(主要是细胞色素P450酶)的激活才能与脱氧核糖核酸结合并启动致癌过程。药物代谢酶的活性和诱导性受遗传、宿主和环境因素之间相互作用的调节。因此,癌症易感性的个体差异在一定程度上可能由代谢激活方面的遗传差异来解释。本文简要回顾了三个例子:多环芳烃对芳烃(苯并[a]芘)羟化酶的诱导、异喹胍/鹰爪豆碱氧化多态性以及乙酰化多态性。尽管有有用的动物模型和早期令人鼓舞的人体研究结果,但对于基于遗传的药物代谢差异在癌症病因学中的重要性尚未达成共识。预计通过使用分子生物学方法,可以不受疾病、年龄、治疗或其他迄今困扰研究的因素所造成的偏差影响,来研究研究对象的遗传背景。